Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24

RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.

Krystal Biotech shares are trading lower after the company announced mixed Q2 financial results.

8-K filing — Krystal Biotech, Inc. (KRYS)

Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Berkshire Hathaway Earnings Preview: Six Months After Warren Buffett Stepped Down, Will CEO Greg Abel Boost Buybacks?

Six months after Warren Buffett stepped down, all eyes are on whether CEO Greg Abel accelerates Berkshire Hathaway's buybacks.

8-K filing — Taylor Morrison Home Corp (TMHC)

Filed: 2026-07-24 AccNo: 0001193125-26-316037 Size: 536 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits